BIOMAT Database Logo BIOMAT Database Logo

[Effects of ponderal on the state of carbohydrate metabolism and insulin secretion in type 2 diabetes mellitus]. 1991

M I Balabolkin, and O M Novikova, and Z I Levitskaia

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D005260 Female Females
D005277 Fenfluramine A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release. Fintepla,Fenfluramine Hydrochloride,Fenfluramine Hydrochloride, (+-)-Isomer,Fenfluramine Hydrochloride, R-Isomer,Fenfluramine, (+-)-Isomer,Fenfluramine, R-Isomer,Isomeride,Pondimin,Fenfluramine Hydrochloride, R Isomer,Fenfluramine, R Isomer,Hydrochloride, Fenfluramine
D005951 Glucose Tolerance Test A test to determine the ability of an individual to maintain HOMEOSTASIS of BLOOD GLUCOSE. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg). Intravenous Glucose Tolerance,Intravenous Glucose Tolerance Test,OGTT,Oral Glucose Tolerance,Oral Glucose Tolerance Test,Glucose Tolerance Tests,Glucose Tolerance, Oral

Related Publications

M I Balabolkin, and O M Novikova, and Z I Levitskaia
Effects of duration of type 2 diabetes mellitus on insulin secretion.
January 2006, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists,
M I Balabolkin, and O M Novikova, and Z I Levitskaia
Ciprofibrate effects on carbohydrate and lipid metabolism in type 2 diabetes mellitus subjects.
February 2000, Nutrition, metabolism, and cardiovascular diseases : NMCD,
M I Balabolkin, and O M Novikova, and Z I Levitskaia
Effects of ketone bodies on carbohydrate metabolism in non-insulin-dependent (type II) diabetes mellitus.
August 1990, Metabolism: clinical and experimental,
M I Balabolkin, and O M Novikova, and Z I Levitskaia
Incretins, insulin secretion and Type 2 diabetes mellitus.
March 2004, Diabetologia,
M I Balabolkin, and O M Novikova, and Z I Levitskaia
Preserving insulin secretion in Type 2 diabetes mellitus.
March 2008, Expert review of endocrinology & metabolism,
M I Balabolkin, and O M Novikova, and Z I Levitskaia
[State of insulin receptors and carbohydrate metabolism in children with diabetes mellitus].
January 1989, Pediatriia,
M I Balabolkin, and O M Novikova, and Z I Levitskaia
[Effects of combined treatment with rosiglitazone and intermediate-acting insulin on carbohydrate metabolism in patients with type 2 diabetes mellitus].
January 2008, Terapevticheskii arkhiv,
M I Balabolkin, and O M Novikova, and Z I Levitskaia
The effects of physical training on insulin secretion and effectiveness and on glucose metabolism in obesity and type 2 (non-insulin-dependent) diabetes mellitus.
December 1985, Diabetologia,
M I Balabolkin, and O M Novikova, and Z I Levitskaia
Abnormalities in insulin secretion in type 2 diabetes mellitus.
February 2008, Diabetes & metabolism,
M I Balabolkin, and O M Novikova, and Z I Levitskaia
Effects of type 2 diabetes on insulin secretion, insulin action, glucose effectiveness, and postprandial glucose metabolism.
May 2009, Diabetes care,
Copied contents to your clipboard!